As the precision medicine industry witnesses exciting Drug-Dx approvals being driven by major advancements in biomarker development, the 12^th Clinical Biomarker & CDx Summit Europe returned in 2022 to set the stage for key learnings with exclusive data to optimise your drug development programmes with the most cutting-edge tools and techniques from start to finish.

Against the backdrop of complex IVDR changes creating industry-wide uncertainty, CB & CDx Europe returned at an all-important moment in time as Europe’s only end-to-end clinical biomarker and CDx summit. Uniting the entire value chain of precision medicine leaders, here they found the latest updates, intelligence and clarity to overcome key portfolio planning hurdles.

Delving deep into the most ground-breaking work enabling patient population identification, and pairing this with revelations from streamlined commercial strategies, this is an industry poised to gain actionable insights maximising access to game-changing precision medicines and testing technology in European markets.

200+ major stakeholders of the European drug-diagnostics field joined to forge successful scientific and commercialization co-development strategies at a pivotal moment for precision medicine.